Login to Your Account



Cubist Submits Cidecin NDA, Could Launch As Early As 2003

By Randall Osborne


Monday, December 23, 2002
Meeting its self-imposed deadline by more than a week, Cubist Pharmaceuticals Inc. submitted the new drug application for injectable Cidecin as a treatment for complicated skin and skin structure infections caused by Gram-positive organisms, including Staphylococcus aureus. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription